PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
12.48%
Revenue growth at 50-75% of ANO.AX's 19.65%. Martin Whitman would worry about competitiveness or product relevance.
18.99%
Gross profit growth under 50% of ANO.AX's 68.87%. Michael Burry would be concerned about a severe competitive disadvantage.
70.35%
EBIT growth above 1.5x ANO.AX's 37.85%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
70.35%
Operating income growth above 1.5x ANO.AX's 37.85%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
107.71%
Net income growth 1.25-1.5x ANO.AX's 80.81%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
100.00%
EPS growth 1.25-1.5x ANO.AX's 80.23%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
100.00%
Diluted EPS growth 1.25-1.5x ANO.AX's 80.23%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
82.12%
Slight or no buybacks while ANO.AX is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
82.12%
Slight or no buyback while ANO.AX is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-274.48%
Negative OCF growth while ANO.AX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-14.34%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-96.30%
Negative 10Y revenue/share CAGR while ANO.AX stands at 270.11%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-57.39%
Negative 5Y CAGR while ANO.AX stands at 56.98%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-55.96%
Negative 3Y CAGR while ANO.AX stands at 49.89%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-103.53%
Negative 10Y OCF/share CAGR while ANO.AX stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
83.39%
OCF/share CAGR of 83.39% while ANO.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-123.37%
Negative 3Y OCF/share CAGR while ANO.AX stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
103.52%
5Y net income/share CAGR above 1.5x ANO.AX's 45.24%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
126.47%
3Y net income/share CAGR above 1.5x ANO.AX's 59.08%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-94.74%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
580.87%
We expand SG&A while ANO.AX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.